If You Invested in LAVA Therapeutics N.V. (LVTX)

LAVA Therapeutics N.V. (former Nasdaq: LVTX) is a clinical-stage biopharmaceutical company that has focused on immuno-oncology and the development of bispecific gamma-delta T cell engagers. The company describes its proprietary Gammabody® platform as a way to engineer bispecific antibodies that selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell anti-tumor effector functions upon cross‑linking to tumor-associated antigens. LAVA has developed several clinical-stage product candidates and preclinical programs aimed at the potential treatment of solid tumors and hematologic malignancies.

Core scientific focus and Gammabody® platform

According to multiple company disclosures, LAVA’s research centers on bispecific gamma-delta T cell engagers. These agents are designed to bind both a tumor-associated antigen on cancer cells and Vγ9Vδ2 T cells, with the goal of redirecting these T cells to lyse cancer cells. The company states that its approach aims to induce tumor cell lysis while limiting off‑target effects, based on preclinical data for its candidates.

LAVA highlights LAVA‑1266 as an internal clinical-stage Gammabody® candidate targeting CD123+ tumor cells for hematologic malignancies, and two partnered clinical-stage programs: PF‑08046052, described as a potential first‑in‑class epidermal growth factor receptor (EGFR) and bispecific gamma-delta T cell receptor‑targeted therapy, and JNJ‑89853413, a bispecific gamma-delta T cell engager targeting CD33 and hematologic cancers. The company also refers to preclinical programs built on the same platform.

Pipeline and key programs

LAVA reports that its pipeline has included:

• LAVA‑1266 (internal): a bispecific gamma-delta T cell engager targeting CD123+ cancers, with a Phase 1, open‑label, multi‑center study (ACTRN12624001214527) in adults with CD123+ relapsed/refractory acute myeloid leukemia (AML) and certain grades of myelodysplastic syndrome (MDS). The study is described as evaluating safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and preliminary anti‑tumor activity.
• JNJ‑89853413 (partnered with Johnson & Johnson): a bispecific gamma-delta T cell engager designed to target CD33 and gamma delta T cells in hematologic cancers. LAVA states that Johnson & Johnson is enrolling patients in a Phase 1, open‑label, multi‑center trial (NCT06618001) in adults with relapsed/refractory AML or higher‑risk MDS.
• PF‑08046052 (partnered with Pfizer Inc.): described as a potential first‑in‑class EGFR‑ and bispecific gamma-delta T cell receptor‑targeted therapy for advanced solid tumors. Pfizer is reported to be enrolling patients in a Phase 1, open‑label, multi‑center study (NCT05983133) in the U.S. and UK.

In various updates, LAVA notes that it has discontinued certain earlier programs, such as LAVA‑1207 and LAVA‑051, and reprioritized its pipeline to focus on LAVA‑1266 while continuing to support its partnered programs.

Corporate developments and acquisition by XOMA Royalty Corporation

LAVA has disclosed a series of strategic and corporate actions culminating in a change of control. On August 3, 2025, the company entered into a Share Purchase Agreement with XOMA Royalty Corporation for a tender offer to acquire all issued and outstanding common shares of LAVA. Subsequent 8‑K filings describe an amended purchase price structure including a cash amount per share and a contingent value right (CVR) per share.

An 8‑K dated November 12, 2025 reports that, as of the expiration of the offer, a majority of LAVA’s outstanding shares had been validly tendered and accepted for payment, and that this satisfied the minimum tender condition. A further 8‑K dated November 21, 2025 states that, following a subsequent offering period, approximately 91.1% of total outstanding shares were tendered, that XOMA Royalty accepted and paid for these shares, and that LAVA became a majority‑owned subsidiary of XOMA Royalty Corporation.

Delisting and reporting status

In connection with the acquisition, LAVA notified The Nasdaq Stock Market LLC of its intention to voluntarily delist its common shares. The 8‑K filed on November 21, 2025 states that Nasdaq suspended trading of LAVA’s shares prior to the opening of trading on November 21, 2025 and filed a Form 25 to remove the shares from listing and registration under Section 12(b) of the Exchange Act. The same filing notes the company’s intention to terminate its reporting obligations by filing a Form 15 with the SEC.

Business restructuring and strategic review

Prior to the completion of the acquisition, LAVA reported a restructuring and strategic review process. Company releases describe:

• An evaluation of strategic alternatives, including potential sale or other transactions, with the stated objective of maximizing shareholder value.
• Restructuring plans, including a reduction of approximately 30% of the global workforce and closure of operations and facilities in the Netherlands, to extend capital resources and align with a focus on LAVA‑1266.
• A waiver of repayment obligations related to an Innovation Credit from the Netherlands Enterprise Agency (RVO), which the company states eliminated a multi‑million‑dollar debt obligation and strengthened its balance sheet.

Position within pharmaceutical preparation manufacturing

Within the broader pharmaceutical preparation manufacturing sector, LAVA has described itself as a clinical-stage immuno‑oncology company with a focus on gamma-delta T cell biology and bispecific antibody engineering. Its activities, as presented in its public disclosures, have centered on advancing its Gammabody® platform, progressing one internal clinical program and multiple partnered programs, and managing its capital structure and corporate strategy through restructuring and an eventual acquisition by XOMA Royalty Corporation.

Frequently asked questions (FAQ)